Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Simbolis: 002693.SZ
SHZ
5.16
CNYRinkos kaina šiandien
2237.9007
P/E santykis
-128.6793
PEG koeficientas
2.14B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 512.21 | 146 | 77 | 100 | ||||||||||||||
balance-sheet.row.short-term-investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.net-receivables | 144.81 | 41 | 33.1 | 44.6 | ||||||||||||||
balance-sheet.row.inventory | 291.75 | 65.4 | 55.2 | 52.8 | ||||||||||||||
balance-sheet.row.other-current-assets | 0.05 | 0 | 0.1 | 0 | ||||||||||||||
balance-sheet.row.total-current-assets | 948.81 | 252.4 | 165.4 | 197.5 | ||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1849.45 | 471.8 | 504.7 | 541 | ||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.long-term-investments | 42.28 | 8.8 | 17.3 | 25.9 | ||||||||||||||
balance-sheet.row.tax-assets | 3.67 | 1 | 1 | 0.7 | ||||||||||||||
balance-sheet.row.other-non-current-assets | 53.66 | 12.2 | 9.1 | 8.3 | ||||||||||||||
balance-sheet.row.total-non-current-assets | 2617.6 | 658.6 | 689.1 | 710.2 | ||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-assets | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.account-payables | 59.55 | 15.5 | 17.2 | 15.4 | ||||||||||||||
balance-sheet.row.short-term-debt | 774.46 | 205.3 | 0.3 | 55.7 | ||||||||||||||
balance-sheet.row.tax-payables | 23.85 | 12.8 | 7.2 | 6.3 | ||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 167 | 167 | ||||||||||||||
Deferred Revenue Non Current | 30.41 | 7.6 | 8.9 | 10.3 | ||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 12.16 | - | - | - | ||||||||||||||
balance-sheet.row.other-current-liab | 144.47 | 73.6 | 1.8 | 1.5 | ||||||||||||||
balance-sheet.row.total-non-current-liabilities | 42.56 | 10.7 | 179.4 | 180 | ||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-liab | 1235.79 | 330.1 | 287.8 | 309.4 | ||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.common-stock | 1662.29 | 414.7 | 412 | 405 | ||||||||||||||
balance-sheet.row.retained-earnings | -1173.2 | -296.2 | -305.2 | -284.6 | ||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1000.92 | 87.2 | 82.2 | 86 | ||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 600.88 | 307.9 | 292.9 | 286.5 | ||||||||||||||
balance-sheet.row.total-stockholders-equity | 2090.9 | 513.5 | 481.8 | 492.9 | ||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.minority-interest | 239.74 | 67.4 | 84.9 | 105.4 | ||||||||||||||
balance-sheet.row.total-equity | 2330.63 | 580.9 | 566.8 | 598.3 | ||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3566.42 | - | - | - | ||||||||||||||
Total Investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.total-debt | 774.46 | 205.3 | 167.3 | 222.7 | ||||||||||||||
balance-sheet.row.net-debt | 709.27 | 193.1 | 145.6 | 216.9 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 16.06 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | 5.29 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 8.3 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -23.72 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | -13.83 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -9.89 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | -5.52 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -0.08 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 30.81 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -418.83 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 456.59 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 29.47 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -60.74 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -8.7 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 38.34 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -31.1 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.02 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 1.46 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 59.79 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 58.33 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | -0.08 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -39.19 | -7.8 | -8.1 | -62.1 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 259.14 | 274.8 | 320.3 | 269.4 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 77.43 | 88.3 | 81.4 | 60.2 | ||||||||||||||
income-statement-row.row.gross-profit | 181.71 | 186.5 | 238.9 | 209.3 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 14.15 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 14.02 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 210.16 | 215.8 | 282.7 | 264.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 287.59 | 304.1 | 364.1 | 324.8 | ||||||||||||||
income-statement-row.row.interest-income | 0.1 | 0.1 | 0.1 | 0.1 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | -9.92 | 57.5 | 54.3 | 57.1 | ||||||||||||||
income-statement-row.row.ebitda-caps | -22.8 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | -12.88 | -24.5 | -42.3 | -53.2 | ||||||||||||||
income-statement-row.row.income-before-tax | -12.93 | -8.9 | -40.4 | -78.8 | ||||||||||||||
income-statement-row.row.income-tax-expense | -8.64 | -0.4 | 0.4 | 1.2 | ||||||||||||||
income-statement-row.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 |
Dažnai užduodami klausimai
Kas yra Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) bendras turtas?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) bendras turtas yra 911018789.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 100763670.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.701.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.095.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.004.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.050.
Kas yra Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -8496001.960.
Kokia yra bendra įmonės skola?
Bendra skola yra 205303152.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 215787255.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 3712099.000.